Evolus, Inc. (EVL.F)

12.20 +0.50 (+4.27%) At close: 08:15AM CEST

Evolus, Inc.

520 Newport Center Drive
Suite 1200
Newport Beach, CA 92660
United States
(949) 284-4555
https://www.evolus.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 273

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David Moatazedi	President, CEO & Director	1.62M	N/A	1978
Ms. Sandra Beaver	Chief Financial Officer	687.1k	N/A	1978
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D.	Chief Medical Officer and Head of Research & Development	764.19k	N/A	1962
Mr. Nareg Sagherian	Head of Global Investor Relations & Corporate Communications	N/A	N/A	N/A
Mr. Jeffrey J. Plumer	General Counsel	N/A	N/A	N/A
Mr. Kurt Knab	Vice President of Sales	N/A	N/A	N/A
Ms. Tomoko Yamagishi-Dressler	Chief Marketing Officer	N/A	N/A	N/A
Ms. Jessica Novak	Senior Vice President of Human Resources	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Corporate governance

Evolus, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.